Cortexyme Inc. (NASDAQ: CRTX): How Can A Stock Be Down -84.55% Year To Date, But Still Loser Cortexyme Inc. (NASDAQ:CRTX)’s traded shares stood at 0.27 million during the last session. At the close of trading, the stock’s price was $1.95, to imply an increase of 2.63% or $0.05 in intraday trading. The CRTX share’s 52-week high remains $121.98, putting it -6155.38% down since that peak but still an impressive 8.72% since price … Cortexyme Inc. (NASDAQ: CRTX): How Can A Stock Be Down -84.55% Year To Date, But Still Loser Read More »
CRTX stock on watch as company plans name change (NASDAQ:CRTX) Alzheimer’s drug developer Cortexyme (CRTX) announced on Wednesday that the company would change its corporate name and ticker symbol with effect from August.Accordingly, Cortexyme…
Analysts Say Cortexyme Inc. (NASDAQ:CRTX) Can Really Get To $12.00 In 12 Months In last trading session, Cortexyme Inc. (NASDAQ:CRTX) saw 0.69 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.52 trading at $0.3 or 13.51% at ring of the bell on the day assigns it a market valuation of $93.79M. That closing price of CRTX’s stock is at … Analysts Say Cortexyme Inc. (NASDAQ:CRTX) Can Really Get To $12.00 In 12 Months Read More »
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after
Cortexyme Inc. (NASDAQ:CRTX) Could Actually Go To $15.00 In 12 Months In last trading session, Cortexyme Inc. (NASDAQ:CRTX) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $3.03 trading at -$0.17 or -5.31% at ring of the bell on the day assigns it a market valuation of $90.05M. That closing price of CRTX’s stock is at … Cortexyme Inc. (NASDAQ:CRTX) Could Actually Go To $15.00 In 12 Months Read More »
Rate - Cortexyme Lowered to Sell at Zacks Investment Research Cortexyme was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks…
Boom Or Bust: What Is Next For Cortexyme Inc. (NASDAQ: CRTX) Stock? Cortexyme Inc. (NASDAQ:CRTX)’s traded shares stood at 0.41 million during the last session. At the close of trading, the stock’s price was $3.53, to imply an increase of 2.32% or $0.08 in intraday trading. The CRTX share’s 52-week high remains $121.98, putting it -3355.52% down since that peak but still an impressive 3.4% since price … Boom Or Bust: What Is Next For Cortexyme Inc. (NASDAQ: CRTX) Stock? Read More »
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves Cortexyme Inc (NASDAQ: CRTX ) has announced additional headcount reductions as part of its previously announced cost reduction program. The restructuring is to rationalize operations and allow continued support for its business needs following the clinical hold on atuzaginstat’s (COR388) Investigational New Drug application. The company is further … Full story available on Benzinga.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm''s Attorneys SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX ) investors who suffered significant losses to submit your losses now . The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit: www.hbsslaw.com/investor-fraud/CRTX Contact An Attorney Now: CRTX@hbsslaw.com 844-916-0895 Cortexyme, Inc. (NASDAQ: CRTX ) Investigation: The investigation focuses on Cortexyme''s statements concerning its Phase II/III clinical trial for its lead drug candidate (atuzaginstat), which is intended to treat patients with mild to moderate Alzheimer''s disease. In the past, Cortexyme has assured investors it has "very good monitoring protocols in place" as a way to mitigate potential safety signals during the trial and that it has seen a "trend to … Full story available on Benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX